Phase 1 COPD Trial, Recruiting NCT06841770 Sponsor: Lineage Cell Therapeutics, Inc. Condition: COPD
Back to Copd

Phase 1 COPD Trial, Recruiting

NCT06841770
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a traumatic spinal cord injury that is either fully affecting both movement and sensation, or affecting only movement but not sensation
  • Your spinal cord injury is located in a specific region of your neck or mid-back (between levels C-4 and T-10) (confirm with trial site)
  • If your injury is recent (subacute), it happened between 21 and 42 days before receiving the study treatment
  • If your injury is longer-standing (chronic), it happened between 1 and 5 years ago, with no signs of improvement for at least 30 days
  • You still have some muscle strength (at least a little movement) in at least one muscle in an arm or hand
  • You are between 18 and 65 years old at the time you give consent to join
  • You have a single injury site, and doctors can clearly see the injury area on scans to monitor your safety after treatment
  • You are able to undergo an elective (planned, non-emergency) surgical procedure at least 21 days after your injury
  • You are willing and able to sign the official consent form for this study
  • If you could become pregnant or could cause a pregnancy, you agree to use contraception for one year after receiving the study treatment

Who may not be able to join:

  • Your spinal cord injury was caused by a penetrating injury, such as a gunshot or stab wound
  • Scans or prior surgery show a complete physical severing, tearing, or inadequate surgical relief of pressure on the spinal cord
  • You have other injuries that would interfere with nerve and muscle testing, such as multiple spinal cord injuries, nerve injuries in the arms or legs, or a traumatic brain injury
  • Scans show a cavity or fluid-filled space in the injury area with an irregular structure that would make the injection procedure unlikely to succeed
  • You have a condition called syringomyelia, meaning progressively growing fluid-filled cysts in the spinal cord linked to worsening symptoms
  • You are unable to communicate well enough with the medical team for reliable neurological testing
  • You have organ damage or a serious illness that would make surgery or immune-suppressing medication too risky
  • You currently require a breathing machine or similar breathing support device (not including simple supplemental oxygen)
  • You have a history of cancer, except certain skin cancers — although if your cancer has been in full remission for more than five years, you may still be considered with special approval (confirm with trial site)
  • You are currently pregnant or breastfeeding
  • You have a spinal cord stimulator device implanted, whether temporary or permanent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 442-287-8940

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Lineage Cell Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
30 June 2025
Est. completion
10 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency and Severity of Adverse Events Related to the Delivery Device or Injection Procedure Through 30 Days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov